Tempest Therapeutics Relocates Principal Executive Offices
Ticker: TPST · Form: 8-K · Filed: Jun 11, 2025 · CIK: 1544227
| Field | Detail |
|---|---|
| Company | Tempest Therapeutics, Inc. (TPST) |
| Form Type | 8-K |
| Filed Date | Jun 11, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: administrative, office-move
TL;DR
Tempest Therapeutics moved its HQ to Brisbane, CA.
AI Summary
On June 11, 2025, Tempest Therapeutics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 2000 Sierra Point Parkway, Suite 400, Brisbane, California, 94005. This move is effective as of the filing date.
Why It Matters
A change in principal executive offices can signal operational shifts or consolidation efforts within a company.
Risk Assessment
Risk Level: low — This filing solely reports a change of address for the company's principal executive offices, which is a routine administrative event.
Key Players & Entities
- Tempest Therapeutics, Inc. (company) — Registrant
- 2000 Sierra Point Parkway, Suite 400, Brisbane, California, 94005 (location) — New principal executive offices
- June 11, 2025 (date) — Date of report and effective date of address change
FAQ
What is the new address for Tempest Therapeutics' principal executive offices?
The new address is 2000 Sierra Point Parkway, Suite 400, Brisbane, California, 94005.
When was this change of address reported?
The change was reported on June 11, 2025.
What type of filing is this?
This is a Form 8-K, a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What was the former company name of Tempest Therapeutics?
The filing mentions former company names including Millendo Therapeutics, Inc. and OvaScience, Inc.
In which state is Tempest Therapeutics incorporated?
Tempest Therapeutics, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 11, 2025 regarding Tempest Therapeutics, Inc. (TPST).